Figure 3.
Auranofin attenuates BCP‐ALL progression and prolongs the survival of leukemic mice. (A) Primograft cells representing MLLr BCP‐ALL were injected into NSG mice, and leukemia progression was monitored weekly through peripheral blood staining with anti‐mCD45, anti‐hCD45, anti‐hCD19 antibodies. Starting from day 31 after the cell injection, randomly selected animals were treated with 10 mg·kg−1 of AUR or control (DMSO) through intraperitoneal injections, once a day for 3 weeks (5 days of treatment/2 days of break schedule, n = 7 for each group). Data are presented as a mean fold of human blasts (hCD45+/hCD19+) over murine leukocytes (mCD45+) ± SD in time from a representative experiment. Depicted P value was calculated by ANOVA with Bonferroni's correction. (B) Kaplan–Meier survival plot presenting event‐free survival of leukemic mice treated with AUR (10 mg·kg−1, n = 10) or vehicle (DMSO, n = 12) for 14 or 15 days. Data are pooled from two independent experiments. Depicted P value was calculated by log‐rank (Mantel–Cox) test.